Skip to main content
Funded Studies

Shanta Bantia, PhD

President and Chief Scientific Officer at Nitor Therapeutics, Inc.

Location: Birmingham, AL United States

Dr. Shanta Bantia is president and chief scientific officer of Nitor Therapeutics, Inc., a biotechnology company in Birmingham, Alabama that is focused on immune diseases, infectious diseases and oncology. Dr. Bantia is a pharmacologist by training, and she introduced the stimulator of interferon genes (STING) target, among other targets, to DiscoveryBioMed (DBM), Inc. In addition to being part of DBM’s accelerator program, Nitor has other asset programs in immunology and oncology in preclinical development. Prior to founding Nitor, Dr. Bantia was a key senior pharmacologist with Biocryst Pharmaceuticals before the company moved from Birmingham to Research Triangle Park in North Carolina, where it continues to focus on the clinical development of several key assets that Dr. Bantia helped discover and develop.

Associated Grants

  • Preclinical Development of Immune-inhibiting Small Molecules as Therapeutics for Parkinson’s Disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.